EP1425580A4 - Materialien und verfahren mit lymphatischen endothelzellen - Google Patents

Materialien und verfahren mit lymphatischen endothelzellen

Info

Publication number
EP1425580A4
EP1425580A4 EP02756453A EP02756453A EP1425580A4 EP 1425580 A4 EP1425580 A4 EP 1425580A4 EP 02756453 A EP02756453 A EP 02756453A EP 02756453 A EP02756453 A EP 02756453A EP 1425580 A4 EP1425580 A4 EP 1425580A4
Authority
EP
European Patent Office
Prior art keywords
methods
endothelial cells
lymphatic endothelial
cells materials
materials
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02756453A
Other languages
English (en)
French (fr)
Other versions
EP1425580A2 (de
Inventor
Kari Alitalo
Taija Makinen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vegenics Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Licentia Oy
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Licentia Oy, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of EP1425580A2 publication Critical patent/EP1425580A2/de
Publication of EP1425580A4 publication Critical patent/EP1425580A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
EP02756453A 2001-07-12 2002-07-12 Materialien und verfahren mit lymphatischen endothelzellen Withdrawn EP1425580A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30488001P 2001-07-12 2001-07-12
US304889P 2001-07-12
US31761001P 2001-09-06 2001-09-06
US317610P 2001-09-06
PCT/US2002/022164 WO2003006104A2 (en) 2001-07-12 2002-07-12 Lymphatic endothelial cells materials and methods

Publications (2)

Publication Number Publication Date
EP1425580A2 EP1425580A2 (de) 2004-06-09
EP1425580A4 true EP1425580A4 (de) 2006-03-29

Family

ID=26974284

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02756453A Withdrawn EP1425580A4 (de) 2001-07-12 2002-07-12 Materialien und verfahren mit lymphatischen endothelzellen

Country Status (7)

Country Link
US (2) US20060269548A1 (de)
EP (1) EP1425580A4 (de)
JP (1) JP2005500045A (de)
CN (1) CN1555488A (de)
AU (1) AU2002322461B2 (de)
CA (1) CA2453161A1 (de)
WO (1) WO2003006104A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2518548C (en) 2003-03-14 2011-12-06 Teikoku Hormone Mfg. Co., Ltd. Peptide fragment of lyve-1 and antibody against the same
JPWO2007013517A1 (ja) * 2005-07-26 2009-02-12 国立大学法人富山大学 リンパ管新生評価系
CA2646497A1 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of circulating endothelial cells
CN101058609B (zh) * 2006-05-26 2011-04-13 神州细胞工程有限公司 人源抗体及其表达
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
EP2125895B1 (de) 2007-02-02 2015-04-08 Vegenics Pty Ltd Vegf-rezeptorantagonisten zur behandlung von allommunität bei organtransplantationen und atherosklerose
ES2526211T3 (es) * 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
WO2009143584A1 (en) * 2008-05-30 2009-12-03 Vegenics Limited Treatment of pulmonary edema
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
US8980264B2 (en) * 2011-03-22 2015-03-17 Japanese Foundation For Cancer Research Mouse anti-Aggrus monoclonal antibodies
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
TW201506036A (zh) * 2013-08-14 2015-02-16 Laurantis Pharma Oy Vegf-c及ccbe1之治療用途
CN105754953B (zh) * 2016-03-17 2019-06-25 苏州大学附属第一医院 抗人平足蛋白血小板聚集区的单克隆抗体及其应用
CN110412262B (zh) * 2019-07-03 2023-09-12 广西医科大学 一种鉴定***内皮细胞的磁性探针及其制备
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
CN115404213A (zh) * 2022-09-16 2022-11-29 华中科技大学 一种肝脏***内皮细胞的分选方法、应用及试剂盒

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6168778B1 (en) * 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6331302B1 (en) * 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
ES2249762T3 (es) * 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5932540A (en) * 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) * 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6818220B1 (en) * 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6221839B1 (en) * 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6403088B1 (en) * 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6245530B1 (en) * 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US6361946B1 (en) * 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
PT848755E (pt) * 1995-09-08 2003-12-31 Genentech Inc Proteina relacionada com o vegf
ATE290077T1 (de) * 1995-09-29 2005-03-15 Univ Siena Regulierte gene und ihre verwendungen
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP2001517075A (ja) * 1996-08-23 2001-10-02 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 組換え血管内皮細胞増殖因子ｄ（ｖｅｇｆ―ｄ）
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US7125714B2 (en) * 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
JP2003517265A (ja) * 1997-12-24 2003-05-27 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 血管内皮増殖因子ｄを発現する発現ベクターおよび細胞系、およびメラノーマを治療する方法
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
DE69931178T8 (de) * 1998-11-02 2007-06-28 Ludwig Institute For Cancer Research Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2
ATE322909T1 (de) * 1998-12-21 2006-04-15 Ludwig Inst Cancer Res Antikörper gegen verkürzten vegf-d und deren verwendungen
CA2381985A1 (en) * 1999-08-16 2001-02-22 Universita'degli Studi Di Siena Vegf-d and angiogenic use thereof
EP1248642A4 (de) * 2000-01-18 2005-05-18 Ludwig Inst Cancer Res Peptidomimetischer inhibitor von vegf sowie vegf-c und -d
US20010038842A1 (en) * 2000-03-02 2001-11-08 Marc Achen Methods for treating various cancers expressing vascular endothelial growth factor D, for screening for a neoplastic disease and for maintaining vascularization of tissue
US20020102260A1 (en) * 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
WO2001082870A2 (en) * 2000-05-03 2001-11-08 Ludwig Institute For Cancer Research A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
NZ518077A (en) * 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
US20020151489A1 (en) * 2000-10-02 2002-10-17 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
US20020197691A1 (en) * 2001-04-30 2002-12-26 Myriad Genetics, Incorporated FLT4-interacting proteins and use thereof
US20030211988A1 (en) * 2001-01-09 2003-11-13 Epstein Stephen E Enhancing lymph channel development and treatment of lymphatic obstructive disease
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
WO2002083849A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
WO2002083850A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP2228389B1 (de) * 2001-04-13 2015-07-08 Human Genome Sciences, Inc. Antikörper gegen vaskulären Endothelwachstumsfaktor 2
US20030180294A1 (en) * 2002-02-22 2003-09-25 Devries Gerald W. Methods of extending corneal graft survival
US20030232437A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-C expression
US20030228283A1 (en) * 2002-05-03 2003-12-11 Ludwig Institute For Cancer Research Preventing secondary lymphedema with VEGF-D DNA

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FITZ L J ET AL: "Characterization of murine Flt4 ligand/VEGF-C.", ONCOGENE, vol. 15, no. 5, 31 July 1997 (1997-07-31), pages 613 - 618, XP002364538, ISSN: 0950-9232 *
MÄKINEN T ET AL: "Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3.", THE EMBO JOURNAL, vol. 20, no. 17, 3 September 2001 (2001-09-03), pages 4762 - 4773, XP002364692, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
JP2005500045A (ja) 2005-01-06
EP1425580A2 (de) 2004-06-09
WO2003006104A3 (en) 2003-04-03
US20060269548A1 (en) 2006-11-30
WO2003006104A2 (en) 2003-01-23
AU2002322461B2 (en) 2007-12-06
CA2453161A1 (en) 2003-01-23
WO2003006104A8 (en) 2004-06-03
CN1555488A (zh) 2004-12-15
US20080317723A1 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
EP1425580A4 (de) Materialien und verfahren mit lymphatischen endothelzellen
EP1487857A4 (de) Gene von endothelzellen aus lymphe und blut
IL138471A0 (en) Novel semiconductor materials and their uses
AU8271101A (en) Titanium-containing materials
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
EP1299168A4 (de) Mini-wirbelabscheider und eindicker für biomasse
DE60111534D1 (de) Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase-aktivatoren
GB0020432D0 (en) Construction materials
AU2002352903A8 (en) Mesoporous materials and methods
DE50112013D1 (de) Deodorantien und antiperspirantien
AU4351201A (en) Heparinase iii and uses thereof
CY2008006I1 (el) Παραγωγα τροπανιου χρησιμα στη θepαπευτικη
GB2392906B (en) Improvements in closures
EP1443951A4 (de) Molekulare wechselwirkungen in zellen
EP1203657A4 (de) Dekoratives material und dekorative platte
EP1443575A4 (de) Positiv-plattenmaterial und zelle damit
IL160772A0 (en) Pancreatic smal cells and uses thereof
EP1572867A4 (de) Endothelzellexpressionsmuster
AU2001229770A1 (en) Improved research and development process
GB0111218D0 (en) Assays methods and means
EP1308571A4 (de) Schalplatte und stützelement dafür
EP1357186A4 (de) Neue proteine und deren dnas
DE60120608D1 (de) Behälteranordnung und Behälter
EP1598325A4 (de) Protonenleitfähiges und elektronenleitfähiges keramik
GB0105667D0 (en) Improvements in insulating materials

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040212

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060210

17Q First examination report despatched

Effective date: 20060823

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VEGENICS LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100202